HB8440, the “ZELDIN Act,” would place new procedural limits on the Environmental Protection Agency when it seeks to end enforcement actions involving releases of certain carcinogens. For covered claims—defined as claims involving chemicals the EPA has identified through IRIS as likely or known human carcinogens—the EPA Administrator could not dismiss an EPA-filed lawsuit or withdraw a referral to the Department of Justice unless Congress first receives notice and then enacts a joint resolution approving the dismissal or withdrawal. The bill also sets out expedited congressional procedures for considering that approval resolution and bars amendments to it.
Beyond litigation decisions, the bill would also constrain EPA grant and cooperative agreement terminations. The Administrator would have to consult with and obtain a compliance determination from EPA’s Office of General Counsel before terminating such awards, and the bill would prohibit termination unless that determination finds the action consistent with applicable OMB/EPA rules and the agreement’s terms. It further protects grant funds from being treated as unobligated or returned to the Treasury until related civil and administrative proceedings are complete, and it limits how other federal agencies may treat a recipient’s failure to close out a disputed grant in future funding decisions or reporting systems.
The bill also codifies certain EPA rulemaking and economic-analysis practices by requiring the agency to use OMB Circular A-4 (2023) for significant regulatory actions and EPA’s 2024 economic analysis guidelines. It creates a private right of action for people harmed by violations of the act, authorizing injunctive relief, damages, attorney’s fees, and enhanced damages for bad-faith violations. A court finding that the Administrator violated the bill’s litigation or grant provisions could also reduce the Administrator’s annual salary to $1 for the next applicable pay period.
The general sentiment reflected by the bill text is strongly regulatory and oversight-oriented, with the measure designed to restrict EPA discretion and increase congressional and legal checks on agency decisions. Because there are no committee transcripts or votes available, there is no recorded floor or committee sentiment to gauge support or opposition. The structure of the bill suggests it is intended to be a forceful response to perceived EPA overreach, especially in environmental enforcement and grant administration.
The main points of contention likely concern separation of powers, agency enforcement discretion, and the practical effect of requiring congressional approval before dismissing environmental lawsuits. Supporters would likely argue the bill increases accountability and prevents politically motivated withdrawals in serious carcinogen cases, while critics would likely view it as an intrusion into executive branch enforcement authority and an added barrier to EPA case management and grant administration. The grant-related provisions may also draw concern from recipients and agencies because they could prolong disputes and complicate funding decisions.
Impact
If enacted, the bill would amend federal law to impose new statutory constraints on EPA enforcement, grant termination, and analytical procedures. It would require congressional approval for dismissing certain EPA lawsuits or withdrawing DOJ referrals involving carcinogens, mandate internal legal review before terminating grants or cooperative agreements, preserve disputed grant obligations during litigation, and create judicial remedies and penalties for violations. It would also effectively codify specific OMB and EPA guidance for regulatory and economic analyses, altering how the EPA conducts significant rulemakings until the bill sunsets in 2029.
Sentiment
No voting record or committee transcript is available, so there is no direct evidence of bipartisan support or opposition from deliberations. Based on the bill’s text, the measure appears to be framed positively by its sponsors as an accountability and anti-abuse measure, but it would likely be controversial among those who favor agency discretion and oppose congressional micromanagement of enforcement and grants. Overall, the available context suggests a partisan or policy-driven proposal rather than a consensus bill.
Contention
The most likely contention is over the requirement that Congress approve EPA dismissals or DOJ referral withdrawals for covered carcinogen claims, which critics may see as an unconstitutional or impractical constraint on executive enforcement authority. Another likely dispute is the bill’s grant provisions, especially the limits on termination, deobligation, and how other agencies may consider unresolved closeout issues in future awards. The codification of specific analytical guidance and the severe salary penalty for the EPA Administrator may also be viewed as unusually punitive or intrusive by opponents, while supporters would likely argue these provisions are necessary to prevent arbitrary agency action.